| Autor: |
Dănilă MD; Department of Functional Sciences - Pathophysiology, 'Victor Babeş' University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041, Timişoara, Romania.; Center for Translational Research and Systems Medicine, 'Victor Babeş' University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041, Timişoara, Romania., Privistirescu A; Department of Functional Sciences - Pathophysiology, 'Victor Babeş' University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041, Timişoara, Romania., Duicu OM; Department of Functional Sciences - Pathophysiology, 'Victor Babeş' University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041, Timişoara, Romania.; Center for Translational Research and Systems Medicine, 'Victor Babeş' University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041, Timişoara, Romania., Rațiu CD; Department of Functional Sciences - Pathophysiology, 'Victor Babeş' University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041, Timişoara, Romania., Angoulvant D; EA 4245 Cellules Dendritiques, Immunomodulation et Greffes, Université François-Rabelais de Tours, 37032, Tours, France.; Service de Cardiologie, Hôpital Trousseau, Centre Hospitalier Régional Universitaire de Tours, 37044, Tours, France., Muntean DM; Department of Functional Sciences - Pathophysiology, 'Victor Babeş' University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041, Timişoara, Romania. daninamuntean@umft.ro.; Center for Translational Research and Systems Medicine, 'Victor Babeş' University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041, Timişoara, Romania. daninamuntean@umft.ro., Sturza A; Department of Functional Sciences - Pathophysiology, 'Victor Babeş' University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041, Timişoara, Romania.; Center for Translational Research and Systems Medicine, 'Victor Babeş' University of Medicine and Pharmacy Timișoara, 2 Eftimie Murgu Sq., 300041, Timişoara, Romania. |
| Abstrakt: |
There is a growing body of evidence pointing to the role of purinergic signaling in the development and progression of various conditions that have inflammation as a common pathogenetic denominator. The aim of the present study was to assess the involvement of P 2 Y 11 purinergic receptors in the regulation of vascular function in aortic segments obtained using an experimental model of acute inflammation, the lipopolysaccharide (LPS, 8 mg/kg, i.p)-treated rats. Twelve hours after LPS administration, thoracic aortas were isolated and used for studies of vascular reactivity in the organ bath and for the measurement of reactive oxygen species (ROS) generation, respectively. LPS treatment significantly increased contractility to phenylephrine and attenuated the endothelium-dependent relaxation of the vascular segments in response to acetylcholine; an increased production of hydrogen peroxide (H 2 O 2 ) was also recorded. The P 2 Y 11 activator, NF 546, decreased the LPS-induced aortic H 2 O 2 release and partially normalized the vasomotor function, namely reduced contractility and improved relaxation. The effect was abolished by co-treatment with the P 2 Y 11 inhibitor, NF 340, and also after endothelium denudation. Importantly, NF 546 did not elicit an antioxidant effect by acting as a H 2 O 2 scavenger, suggesting that the beneficial outcome of this treatment on the vasculature is the consequence of P 2 Y 11 stimulation. In conclusion, purinergic P 2 Y 11 receptors stimulation improves vascular function and mitigates oxidative stress in the setting of acute systemic inflammation, revealing salutary effects and therapeutic potential in pathologies associated with endothelial dysfunction. |
Full text from SpringerLink